Episurf Medical CMD and Q3 results - DNB

Episurf Medical hosted a CMD on 16 November at which it discussed the state of the company and its long-term plans. International expansion will be even more important in the future, in our view. The company is still suffering from the effects of the pandemic, and Q3 sales were thus lower than we expected, though its operating losses were in line with our forecast. We reiterate our fair value for Episurf of SEK3.3–9.3.

Länk till analysen i sin helhet: https://www.dnb.no/seg-fundamental/fundamentalweb/GetReportSpon.aspx?file=CMPSP_204845.pdf